drugset
drugset / Trial / NCT00757341

Study Evaluating The Mass Balance And Metabolic Disposition Of SKI-606

NCT00757341 ↗

Phase 1 Completed 6 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the mass balance, metabolic disposition, and identification of metabolites following single oral administration of \[14C\]-SKI-606 in healthy male subjects.

Timeline

Start
2008-12
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule — Oral

Indications

No indication recorded.